GLP-1 agonists including semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) have been approved by the Food and Drug Administration for chronic weight management in adults with obesity or those who are overweight and have at least 1 weight-related condition. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.